Monalizumab

Monalizumab, a humanized anti-NKG2A antibody is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers.

Mechanism of action

Monalizumab is a monoclonal antibody targeted at NKG2A. It is a checkpoint inhibitor.